Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.
Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L. Antolín S, et al. Breast Cancer (Dove Med Press). 2018 Dec 27;11:29-42. doi: 10.2147/BCTT.S179750. eCollection 2019. Breast Cancer (Dove Med Press). 2018. PMID: 30643452 Free PMC article.
Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study.
Valladares-Ayerbes M, Iglesias-Díaz P, Díaz-Prado S, Ayude D, Medina V, Haz M, Reboredo M, Antolín S, Calvo L, Antón-Aparicio LM. Valladares-Ayerbes M, et al. Among authors: antolin s. J Cancer Res Clin Oncol. 2009 Sep;135(9):1185-95. doi: 10.1007/s00432-009-0559-7. Epub 2009 Feb 17. J Cancer Res Clin Oncol. 2009. PMID: 19221791 Free article. Clinical Trial.
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A, Ruiz A, Plazaola A, Calvo L, Seguí MA, Santaballa A, Muñoz M, Sánchez P, Miguel A, Carrasco E, Lao J, Camps J, Alfaro J, Antolín S, Cámara MC. Antón A, et al. Among authors: antolin s. Ann Oncol. 2011 Jan;22(1):74-79. doi: 10.1093/annonc/mdq317. Epub 2010 Jul 5. Ann Oncol. 2011. PMID: 20603435 Free article. Clinical Trial.
Breast cancer management in the elderly.
Luque M, Arranz F, Cueva JF, de Juan A, García-Teijido P, Calvo L, Peláez I, García-Palomo A, García-Mata J, Antolín S, García-Estévez L, Fernández Y. Luque M, et al. Among authors: antolin s. Clin Transl Oncol. 2014 Apr;16(4):351-61. doi: 10.1007/s12094-013-1113-2. Epub 2013 Oct 2. Clin Transl Oncol. 2014. PMID: 24085574 Review.
Circulating miR-200c and miR-141 and outcomes in patients with breast cancer.
Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I, Figueroa A, Antón-Aparicio LM, Valladares-Ayerbes M. Antolín S, et al. BMC Cancer. 2015 Apr 2;15:297. doi: 10.1186/s12885-015-1238-5. BMC Cancer. 2015. PMID: 25885099 Free PMC article.
Physical activity and breast cancer risk by pathological subtype.
Lope V, Martín M, Castelló A, Casla S, Ruiz A, Baena-Cañada JM, Casas AM, Calvo L, Bermejo B, Muñoz M, Ramos M, de Juan-Ferré A, Jara C, Antón A, Jimeno MÁ, Lluch A, Antolín S, García-Sáenz JÁ, Estévez P, Arriola-Arellano E, Gavilá J, Pérez-Gómez B, Carrasco E, Pollán M; GEICAM, the Spanish Breast Cancer Group. Lope V, et al. Among authors: antolin s. Gynecol Oncol. 2017 Mar;144(3):577-585. doi: 10.1016/j.ygyno.2016.12.014. Epub 2017 Jan 3. Gynecol Oncol. 2017. PMID: 28057355
Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.
Cueva JF, Antolín S, Calvo L, Fernández I, Ramos M, de Paz L, Mata JG, López R, Constenla M, Pérez E, González A, Pellón ML, Varela S, López T. Cueva JF, et al. Among authors: antolin s. Clin Transl Oncol. 2017 Sep;19(9):1067-1078. doi: 10.1007/s12094-017-1648-8. Epub 2017 Mar 24. Clin Transl Oncol. 2017. PMID: 28342058 Free PMC article.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Martín M, Chacón JI, Antón A, Plazaola A, García-Martínez E, Seguí MA, Sánchez-Rovira P, Palacios J, Calvo L, Esteban C, Espinosa E, Barnadas A, Batista N, Guerrero A, Muñoz M, Romio E, Rodríguez-Martín C, Caballero R, Casas MI, Rojo F, Carrasco E, Antolín S. Martín M, et al. Among authors: antolin s. Oncologist. 2017 Nov;22(11):1301-1308. doi: 10.1634/theoncologist.2017-0052. Epub 2017 Jul 12. Oncologist. 2017. PMID: 28701571 Free PMC article. Clinical Trial.
50 results